Australia - angielski - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol - bortezotero in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezotero as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezotero is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezotero in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Filipiny - angielski - FDA (Food And Drug Administration)

euro-generics int'l phils inc - aciclovir - tablet - 400mg

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

idaman pharma manufacturing sdn. bhd. - cloxacillin sodium -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

idaman pharma manufacturing sdn. bhd. - cloxacillin sodium -

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hetero labs limited - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 1 mg - finasteride tablets usp are indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only. efficacy in bitemporal recession has not been established. finasteride tablets usp are not indicated for use in women. finasteride tablets usp are contraindicated in the following:  • pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. [see warnings and precautions (5.1), use in specific populations (8.1), how supplied/storage and handling (16) and patient counseling information (17.1).] in female rats, low doses of finast

Izrael - angielski - Ministry of Health

abic marketing ltd, israel - finasteride - film coated tablets - finasteride 1 mg - finasteride - finasteride - finasteride teva 1 mg is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - finasteride 1mg - film coated tablet - 1 mg - active: finasteride 1mg excipient: docusate sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry brown 03a86790 pregelatinised maize starch purified water sodium starch glycolate - pharmacare finasteride 1 mg film coated tablets: finasteride is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss. finasteride is not indicated for use in women (see warnings and precautions, pregnancy) or children. finasteride is not effective in postmenopausal women with androgenetic alopecia.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hetero drugs limited - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 5 mg - finasteride tablets usp are not approved for the prevention of prostate cancer.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lauroyl macrogolglycerides; lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - finasteride gh 5 5 mg is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; lauroyl macrogolglycerides; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - finasteride gh 1 mg is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. finasteride gh 1 mg is not indicated for use in women (see use in pregnancy and clinical studies) or children.